People: ARIAD Pharmaceuticals Inc (ARIA.O)

Summary

Name	Age	Since	Current Position
Harvey Berger	62	2004	Chairman of the Board, President, Chief Executive Officer
Edward Fitzgerald	57	2010	Chief Financial Officer, Executive Vice President, Treasurer
Raymond Keane	53	2009	Senior Vice President, General Counsel, Secretary and Chief Compliance Officer
David Berstein	60	2008	Senior Vice President, Chief Intellectual Property Officer
Daniel Bollag	51	2009	Senior Vice President - Regulatory Affairs and Quality
Maria Cantor	44	2012	Senior Vice President - Corporate Affairs
Pierre Dodion	57	2012	Senior Vice President - Corporate Development and Operations
Martin Duvall	50	2011	Senior Vice President - Commercial Operations
Frank Haluska	53	2012	Senior Vice President - Clinical Research and Development and Chief Medical Officer
Timothy Clackson	47	2010	President - Research and Development, Chief Scientific Officer
Athanase Lavidas	64	2008	Lead Independent Director
Jay LaMarche	65	2000	Independent Director
Massimo Radaelli	54	2008	Independent Director
Norbert Riedel		2011	Independent Director
Robert Whelan	60	2010	Independent Director
Wayne Wilson	63	2008	Independent Director

» Insider Trading

Biographies

Name	Description
Harvey Berger	Dr. Harvey J. Berger, M.D., is Chairman of the Board, President, Chief Executive Officer of Ariad Pharmaceuticals, Inc. He is principal founder and has served as Chairman of the Board and Chief Executive Officer since April 1991. He served as President from April 1991 to September 2003 and from December 2004 to present. He is chair of the Executive Committee. From 1986 to 1991, Dr. Berger held a series of executive management positions at Centocor, Inc., a biotechnology company, including Executive Vice President and President, Research and Development Division. He has also held senior academic and administrative appointments at Emory University, Yale University and the University of Pennsylvania and was an Established Investigator of the American Heart Association. Dr. Berger currently serves as a member of the Dean’s Council of Yale School of Medicine. Dr. Berger received his A.B. degree in Biology from Colgate University and his M.D. degree from Yale University School of Medicine. He obtained further medical and research training at the Massachusetts General Hospital and Yale-New Haven Hospital.
Edward Fitzgerald	Mr. Edward M. Fitzgerald is Chief Financial Officer, Executive Vice President, Treasurer of Ariad Pharmaceuticals, Inc. since June 2010. Previously, he served as Senior Vice President, Chief Financial Officer and Treasurer from May 2002 to June 2010. From 1998 to April 2002, he served as Senior Vice President, Chief Financial Officer and Secretary at AltaRex Corp., a biotechnology company. From 1992 to 1997, Mr. Fitzgerald held various management positions at BankBoston Corp., a financial services and commercial banking company. From 1989 to 1992, he was a partner at Arthur Andersen & Co. in the audit and business advisory practice. Previously, from 1978 to 1988, he also was at Arthur Andersen & Co. Mr. Fitzgerald received his B.S. degree in accounting and M.B.A. degree in finance from Babson College.
Raymond Keane	Mr. Raymond T. Keane, Esquire, is Senior Vice President, General Counsel, Secretary and Chief Compliance Officer of Ariad Pharmaceuticals, Inc. since January 2009. Previously, he was the company's Vice President, General Counsel and Chief Compliance Officer. Prior to joining the company in May 2008, Mr. Keane spent twenty years with Bristol-Myers Squibb Company (BMS), most recently as Senior Counsel, Worldwide Medicines and previously as lead counsel to various therapeutic divisions, including BMS Oncology/Immunology. While at BMS, he had primary legal responsibility for the commercialization and launch of seven BMS products. Before joining BMS in 1988, Mr. Keane was an associate with the law firms of Wilson, Elser, Moskowitz, Edelman & Dicker from 1987 to 1988 and Martin, Clearwater and Bell from 1984 to 1987. He received his J.D. degree from Fordham University School of Law and his B.A. degree in Economics from Fordham University.
David Berstein	Mr. David L. Berstein, Esquire, is Senior Vice President and Chief Intellectual Property Officer of Ariad Pharmaceuticals, Inc. since May 2008. Mr. Berstein also served as Senior Vice President and Chief Patent Counsel from June 2003 until June 2007 and Vice President and Chief Patent Counsel from September 1993 to June 2000. From July 2007 until his return to company in May 2008, Mr. Berstein was Senior Vice President and Chief Patent Counsel for Tempo Pharmaceuticals, Inc., a biotechnology company. During this time period, he was a consultant to the company on intellectual property matters. From 1990 through 1993, Mr. Berstein was Patent Counsel at BASF Bioresearch Corporation, a biotechnology company, where he was responsible for intellectual property matters, including patents and licensing. From 1985 to 1990, Mr. Berstein was a patent attorney at Genetics Institute, Inc., a biotechnology company, where he was involved in various aspects of the patent process from patent procurement through litigation. Mr. Berstein joined Genetics Institute from the law firm of Cooper & Dunham. Mr. Berstein received his B.S. degree from the University of Michigan and his J.D. degree from Fordham University School of Law.
Daniel Bollag	Dr. Daniel M. Bollag, Ph.D. is Senior Vice President - Regulatory Affairs and Quality of Ariad Pharmaceuticals, Inc. since January 2009. He previously served as Vice President, Regulatory Affairs for Genzyme Corporation, a biotechnology company, from 2006 to 2008. From 2002 to 2006, Dr. Bollag held multiple positions at Sanofi-Aventis Pharmaceuticals, including Associate Vice President, Global Regulatory Domain Head. Dr. Bollag also served as Director, Project Planning and Management at Bristol-Myers Squibb from 2000 to 2002. Earlier in his career, he held positions at Merck. Dr. Bollag received his B.S. degree in Science and B.A. degree in French at Pennsylvania State University and his Ph.D. degree in Biochemistry from Cornell University. He also completed a postdoctoral fellowship at Princeton University.
Maria Cantor	Ms. Maria E. Cantor is Senior Vice President - Corporate Affairs of Ariad Pharmaceuticals Inc. since January 2012. Previously she served as Vice President, Corporate Communications and Investor Relations since July 2008. Prior to joining the company, Ms. Cantor held several positions of increasing responsibility at Genzyme Corporation from 2001 to 2008, most recently serving as Senior Director, Corporate Communications. From 2000 to 2001, she held the position of Director, Public Relations and Marketing at St. Elizabeth’s Medical Center of Boston. From 1994 to 2000, Ms. Cantor held director positions in marketing and public relations at Optima Healthcare, Inc. and Catholic Medical Center. Prior to 1994, she was Assistant Press Secretary to former U.S. Congressman, Martin T. Meehan and served as News Anchor/Reporter at a Massachusetts broadcast station. She received her M.S. degree in communications management from Syracuse University and her B.S. degree from Emerson College.
Pierre Dodion	Dr. Pierre F. Dodion, M.D., M.B.A., is Senior Vice President - Corporate Development and Operations of Ariad Pharmaceuticals, Inc. since February 2012. He has been Senior Vice President, Corporate Development from July 2010 to January 2012. Previously, he served as Senior Vice President and Chief Medical Officer from April 2008 to June 2010 and as Senior Vice President, Oncology from June 2007 to April 2008. From 2006 to 2007, Dr. Dodion served as Executive Director, Oncology at Pfizer Inc. From 2002 to 2006, he held senior positions at Novartis in the Oncology Business Unit, most recently as Executive Director, Global Strategy and Global Marketing. From 1997 to 2002, Dr. Dodion served as Medical Director and later as Senior Medical Director at Aventis. Prior to Aventis, he held medical and scientific positions at UBC S.A. and Roche Pharmaceuticals. Previously, he held positions at Institut Jules Bordet at the Free University of Brussels and the National Cancer Institute. Dr. Dodion received his M.D. degree from the Free University of Brussels in Belgium and his M.B.A. degree from St. Joseph University in Philadelphia, Pennsylvania.
Martin Duvall	Mr. Martin J. Duvall is Senior Vice President - Commercial Operations of ARIAD Pharmaceuticals, Inc., since September 2011. Prior to joining the company, Mr. Duvall served as Senior Vice President and General Manager of Merck and Company’s global oncology franchise. From 2009 to 2010, Mr. Duvall led global marketing and commercial operations at Abraxis Bioscience, Inc. From 2004 to 2009, Mr. Duvall held commercial operations, commercial development and oncology strategy for MGI Pharma, Inc. and its acquirer, Eisai. Earlier in his career, from 1986 to 2004, he held numerous oncology marketing and sales roles at Sanofi-Aventis and its predecessor companies, including a leadership role in the global development, commercialization and strategic direction of the company’s cytotoxic chemotherapy drugs. He received his B.S. degree in Chemistry from Muhlenberg College, his M.A. degree in Chemistry from the Johns Hopkins University and his M.B.A degree from the University of Kansas.
Frank Haluska	Dr. Frank G. Haluska, M.D., Ph.D., is Senior Vice President - Clinical Research and Development and Chief Medical Officer of Ariad Pharmaceuticals, Inc., since January 2012, having held the position of Vice President and Chief Medical Officer since June 2010. Previously, he served as the Vice President, Clinical Affairs from May 2009 to June 2010, Vice President, Clinical Research from July 2008 to May 2009, and Senior Medical Director from October 2007 to July 2008. Prior to joining the company, Dr. Haluska served as a senior faculty member in the departments of medicine and genetics at Tufts University School of Medicine from 2005 to 2007, where he also was Clinical Director and Deputy Director of the Tufts-New England Medical Center Cancer Center. From 1994 to 2005, he held positions in academia, medical research and clinical oncology at centers of excellence, including assistant professor of medicine at Harvard Medical School, and leader of the melanoma research programs at Dana-Farber Cancer Institute and Massachusetts General Hospital Cancer Center. Dr. Haluska is Colonel in the Medical Corps of the United States Air Force and the Massachusetts Air National Guard. He completed a post-doctoral fellowship at the Massachusetts Institute of Technology, fellowship training in medical oncology at Dana Farber Cancer Institute, and his training in internal medicine at Massachusetts General Hospital. He received his M.D. degree and Ph.D. degree from the University of Pennsylvania School of Medicine and A.B. degree from Harvard University.
Timothy Clackson	Dr. Timothy P. Clackson, Ph.D., is President - Research and Development, Chief Scientific Officer of Ariad Pharmaceuticals, Inc. since June 2010. Previously, he served as Senior Vice President and Chief Scientific Officer from September 2003 to June 2010, as Senior Vice President, Science and Technology from June 2002 to September 2003, as Vice President, Gene Therapy and Genomics from June 2000 to June 2002, and in a series of additional research and research management positions since joining the company in December 1994. Dr. Clackson led the multi-disciplinary research group that discovered product candidates, ponatinib, AP26113, and ridaforolimus. From 1991 to 1994, Dr. Clackson was a postdoctoral research fellow in protein engineering at Genentech, Inc., a biotechnology company. Dr. Clackson received his B.A. degree in Biochemistry from the University of Oxford, and his Ph.D. degree in Biology from the University of Cambridge for research conducted at the MRC Laboratory of Molecular Biology that included the development of antibody phage display technology.
Athanase Lavidas	Dr. Athanase Lavidas, Ph.D., is Lead Independent Director of Ariad Pharmaceuticals, Inc. since November 2008. He has been Chairman and Chief Executive Officer of the Lavipharm Group, a pharmaceutical, cosmetics and consumer health products company headquartered in Greece, since 1976. Dr. Lavidas is also Chairman of the Greece-U.S. Business Council and Vice Chairman of the Board of Hellenic Federation of Industries and Enterprises, Head of International Affairs. Dr. Lavidas has been a member of Board since September 2003. He is chair of the Nominating and Corporate Governance Committee and a member of the Executive Committee and the Compensation Committee.
Jay LaMarche	Mr. Jay R. LaMarche is Independent Director of Ariad Pharmaceuticals, Inc. since January 1992. He has served the company for over twenty years as a director and in executive leadership positions including Chief Financial Officer and Treasurer from January 1992 to November 2000. Mr. LaMarche was Executive Vice President from March 1997 to November 2000 and Senior Vice President, Finance from January 1992 to February 1997. Prior to joining ARIAD, he was Chief Financial Officer and a director of ChemDesign Corporation, a chemicals manufacturer. Previously, Mr. LaMarche was an audit partner with Deloitte Haskins & Sells, a public accounting firm. Mr. LaMarche also served as an officer in the United States Navy. He is a member of the Audit Committee and the Nominating and Corporate Governance Committee. Mr. LaMarche received his B.B.A. degree in Public Accountancy from the University of Notre Dame.
Massimo Radaelli	Dr. Massimo Radaelli, Ph.D., is Independent Director of Ariad Pharmaceuticals, Inc. since October 2008. He is President and Chief Executive Officer of Noventia Pharma, a specialty pharmaceutical company with headquarters in Lausanne, Switzerland focused on rare diseases and orphan drugs (CNS and Respiratory). Dr. Radaelli brings over twenty-five years of industry experience to Board, including senior leadership positions with European pharmaceutical companies. Prior to joining Noventia in May 2009, Dr. Radaelli was President and Chief Executive Officer of Dompé International SA, the international pharmaceutical company of the Dompé Group. He joined Dompé in 1996 as director of corporate business development. Previously, Dr. Radaelli held various sales and marketing positions at the Dupont-Merck Pharmaceutical Company, the Menarini Group, and Hoffman-La Roche Ltd. Dr. Radaelli is also the Executive Chairman of Bioakos Pharma Laboratories, a specialty pharmaceuticals company concentrated in the fields of gynecology, dermatology, ENT and pediatrics. He also serves as a director of Arriani International, SA, the international subsidiary of Arriani Pharmaceuticals, a pharmaceutical company in Southeastern Europe, and a director of Lavipharm svl, the Italian subsidiary of Lavipharm Group, a pharmaceutical, cosmetics and consumer health products company headquartered in Greece. He is chair of the Compensation Committee and a member of the Audit Committee. Since June 2011, Dr. Radaelli has also served on the Nominating and Corporate Governance Committee. Dr. Radaelli received a University Degree in pharmaceutical sciences and a Ph.D. in clinical pharmacology from the University of Milan and an Executive Master of Business from Bocconi University of Milan.
Norbert Riedel	Dr. Norbert G. Riedel, Ph.D., is Independent Director of ARIAD Pharmaceuticals, Inc. He is Corporate Vice President and Chief Scientific Officer of Baxter International Inc., a diversified healthcare company, having served in that capacity since March 2001. Before assuming this role, from 1998 to 2001, Dr. Riedel served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development at Baxter’s BioScience business. Prior to joining Baxter, from 1996 to 1998, he was head of worldwide biotechnology and worldwide core research functions at Hoechst-Marion Roussel, now Sanofi-Aventis, a global pharmaceutical company. Previously, he held a series of scientific management positions at Hoechst-Marion Roussel and Hoechst AG. Dr. Riedel has been a member of the Supervisory Board of MediGene, AG, a biotechnology company, since 2003. He is a member of the Board of Directors of the Illinois Biotechnology Industry Organization and also serves on the Advisory Board of Northwestern University’s Kellogg School of Management Center for Biotechnology, and the McCormick School of Engineering. Most recently, he was appointed by Illinois Governor Pat Quinn to the newly formed Illinois Innovation Council. From 1999 to 2010, Dr. Riedel was a member of the board of directors of Oscient Pharmaceuticals Corporation, a biopharmaceutical company, and its predecessor company, Genome Therapeutics Corporation, a genomics company.
Robert Whelan	Mr. Robert M. Whelan, Jr., is Independent Director of Ariad Pharmaceuticals, Inc. He has over thirty-five years of investment banking experience working predominantly with high technology and healthcare companies. He has been the President of Whelan & Company, LLC, providing business and financial consulting and strategic services to a broad range of companies, since 2001. From 2001 to 2005, Mr. Whelan served as Managing Director of Valuation Perspectives, Inc., a consulting firm. Prior to that, he held a number of senior-level positions at various investment banking and brokerage firms. Mr. Whelan was Vice Chairman of Prudential Volpe Technology Group, the technology investment banking and research division of Prudential Securities. Prior to Prudential Volpe, he was Chief Operating Officer, Managing Director, board member and Head of Investment Banking of Volpe Brown Whelan & Company, a private technology and healthcare investment banking, brokerage and asset management firm. Volpe Brown Whelan & Company was acquired by Prudential Securities in 1999. From 2008 to 2009, Mr. Whelan was a Fellow at the Harvard University Advanced Leadership Initiative, an innovative year-long program aimed at providing a rigorous educational curriculum for exceptional leaders who have reached the height of their professions and are seeking to contribute their skills to solve global social problems. Since May 2010, he has served on the Audit Committee and Compensation Committee. Mr. Whelan received a B.A. in history from Dartmouth College and a M.B.A. from Stanford University Graduate School of Business.
Wayne Wilson	Mr. Wayne Wilson is Independent Director of Ariad Pharmaceuticals, Inc. since October 2008. He has over thirty years of business, financial, and accounting experience. He has been an independent business advisor since 2002. From 1995 to 2002, he served in various roles, including as President, Chief Operating Officer, and Chief Financial Officer, at PC Connection, Inc., a Fortune 1000, direct marketer of information technology products and services. From 1986 to 1995, Mr. Wilson was a partner in the assurance and advisory services practice of Deloitte & Touche LLP. Mr. Wilson has been a member of the Board since October 2008. He is chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee and the Executive Committee. Mr. Wilson is also a member of the boards of directors of Fairpoint Communications, Inc., a telecommunications company, Hologic, Inc., a medical diagnostics and device company focusing on women’s health, and Edgewater Technology, Inc., a technology management consulting firm. He previously served as a director of Cytyc Corporation, a medical diagnostics and device company. Mr. Wilson received an A.B. degree in political science from Duke University and an M.B.A. from the University of North Carolina at Chapel Hill.

Basic Compensation

Name	Fiscal Year Total
Harvey Berger	3,859,660
Edward Fitzgerald	1,295,370
Raymond Keane	--
David Berstein	744,434
Daniel Bollag	779,877
Maria Cantor	--
Pierre Dodion	558,946
Martin Duvall	1,157,540
Frank Haluska	1,038,590
Timothy Clackson	1,438,280
Athanase Lavidas	--
Jay LaMarche	223,592
Massimo Radaelli	--
Norbert Riedel	--
Robert Whelan	--
Wayne Wilson	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Harvey Berger	770,192	1,489,756
Edward Fitzgerald	243,000	217,350
Raymond Keane	0	0
David Berstein	409,571	471,691
Daniel Bollag	0	0
Maria Cantor	0	0
Pierre Dodion	0	0
Martin Duvall	0	0
Frank Haluska	0	0
Timothy Clackson	283,160	763,498
Athanase Lavidas	0	0
Jay LaMarche	286,357	1,107,673
Massimo Radaelli	0	0
Norbert Riedel	0	0
Robert Whelan	0	0
Wayne Wilson	0	0

Insider Trading

Name	Shares Traded	Price
BERGER HARVEY J	2,700	$18.14
BERGER HARVEY J	37,098	$18.22
BERGER HARVEY J	2,700	$18.00
BERGER HARVEY J	50,000	$18.01
BERGER HARVEY J	5,400	$18.00
BERGER HARVEY J	100,000	$18.01
CANTOR MARIA E	4,250	$18.04
FITZGERALD EDWARD M	5,200	$18.04
BERSTEIN DAVID L	2,400	$18.05
CLACKSON TIMOTHY P	6,500	$18.04
HALUSKA FRANK G	3,400	$18.04
KEANE RAYMOND T	2,583	$18.05
BOLLAG DANIEL M	2,400	$18.05
DODION PIERRE F	2,400	$18.04
BOLLAG DANIEL M	6,000	$0.00
HALUSKA FRANK G	8,500	$0.00
CANTOR MARIA E	8,500	$0.00
BERGER HARVEY J	41,666	$0.00
CLACKSON TIMOTHY P	13,000	$0.00
FITZGERALD EDWARD M	13,000	$0.00
BERSTEIN DAVID L	6,000	$0.00
KEANE RAYMOND T	5,166	$0.00
BERGER HARVEY J	19,688	$18.30
DODION PIERRE F	6,000	$0.00
FITZGERALD EDWARD M	12,933	$18.75

» Full list on Insider Trading

People: ARIAD Pharmaceuticals Inc (ARIA.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: